QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics - LCTX Earnings Date, Estimates & Call Transcripts

$1.43
+0.01 (+0.70%)
(As of 02/6/2023 05:19 PM ET)
Add
Compare
Today's Range
$1.39
▼
$1.46
50-Day Range
N/A
52-Week Range
$1.02
▼
$1.79
Volume
525,660 shs
Average Volume
341,815 shs
Market Capitalization
$243.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.40

Earnings Summary

Upcoming
Earnings Date
Mar. 8Estimated
Actual EPS
(Nov. 10)
-$0.04 Missed By -$0.01
Consensus EPS
(Nov. 10)
-$0.03
Last Year's Q4 EPS
(11/10/2021)
-$0.05
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

LCTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LCTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Lineage Cell Therapeutics Analyst Forecasts

Current Year EPS Consensus Estimate: $-0.15 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS

LCTX Earnings Date and Information

Lineage Cell Therapeutics last issued its earnings results on November 10th, 2022. The reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business earned $3 million during the quarter, compared to the consensus estimate of $4.11 million. Lineage Cell Therapeutics has generated ($0.29) earnings per share over the last year (($0.29) diluted earnings per share). Earnings for Lineage Cell Therapeutics are expected to decrease in the coming year, from ($0.15) to ($0.17) per share. Lineage Cell Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 8th, 2023 based off prior year's report dates.

Lineage Cell Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/8/2023
(Estimated)		        
11/10/2022Q3 2022($0.03)($0.04)($0.01)($0.04)$4.11 million$3.00 million
8/11/2022Q2 2022($0.03)($0.04)($0.01)($0.04)$4.86 million$4.55 million
5/12/2022Q1 2022$0.01($0.04)($0.05)($0.04)$12.07 million$5.24 million
3/10/2022Q4 2021($0.04)($0.05)($0.01)$0.07$1.20 million$1.20 million    
11/10/20219/30/2021($0.05)($0.05)($0.05)$0.56 million$2.27 million    
8/12/20216/30/2021($0.03)($0.03)($0.03)$1.05 million$0.51 million    
5/13/20213/31/2021($0.04)($0.01)+$0.03($0.11)$1.07 million$0.39 million  
3/10/202112/31/2020($0.05)$0.01+$0.06$0.01$1.34 million$0.36 million  
11/4/2020Q3 2020($0.05)($0.04)+$0.01($0.03)$0.65 million$0.57 million
11/4/2020Q3 2020($0.05)($0.04)+$0.01($0.03)$0.65 million$0.57 million
11/4/20209/30/2020($0.05)($0.05)($0.03)$0.65 million$0.57 million  
8/6/2020Q2 2020($0.04)($0.04)($0.04)$0.76 million$0.39 million
8/6/2020Q2 2020($0.04)($0.04)($0.04)$0.76 million$0.39 million
8/6/20206/30/2020($0.04)($0.04)($0.04)$0.76 million$0.39 million  
5/7/2020Q1 2020($0.05)($0.06)($0.01)($0.06)$0.93 million$0.51 million
5/7/2020Q1 2020($0.05)($0.06)($0.01)($0.06)$0.93 million$0.51 million
5/7/20203/31/2020($0.05)($0.06)($0.01)($0.06)$0.93 million$0.51 million  
3/12/2020Q4 2019($0.07)($0.03)+$0.04($0.03)$0.60 million$1.24 million
3/12/2020Q4 2019($0.07)($0.03)+$0.04($0.03)$0.60 million$1.24 million  
3/12/202012/31/2019($0.07)($0.03)+$0.04($0.03)$0.60 million$1.24 million  
11/12/2019Q3 2019($0.05)($0.04)+$0.01$0.03$0.94 million$0.57 million
11/12/2019Q3 2019($0.05)($0.04)+$0.01$0.03$0.94 million$0.57 million
11/12/2019Q3 2019($0.05)($0.04)+$0.01$0.03$0.94 million$0.57 million
8/8/2019Q2 2019($0.05)($0.06)($0.01)$0.08$1.04 million$0.78 million
8/8/2019Q2 2019($0.05)($0.06)($0.01)$0.08$1.04 million$0.78 million
8/8/2019Q2 2019($0.05)($0.06)($0.01)$0.08$1.04 million$0.78 million
5/9/2019Q1 2019($0.06)$0.30+$0.36$0.30$0.66 million$0.93 million
5/9/2019Q1 2019($0.06)$0.30+$0.36$0.30$0.66 million$0.93 million
5/9/2019Q1 2019($0.06)$0.30+$0.36$0.30$0.66 million$0.93 million
3/14/2019Q4 2018($0.07)($0.07)$0.21$0.74 million$0.76 million
3/14/2019Q4 2018($0.07)($0.07)$0.21$0.74 million$0.76 million
3/14/2019Q4 2018($0.07)($0.07)$0.21$0.74 million$0.76 million
11/8/2018Q3 2018($0.06)($0.07)($0.01)($0.67)$0.75 million$0.98 million
11/8/2018Q3 2018($0.06)($0.07)($0.01)($0.67)$0.75 million$0.98 million
11/8/2018Q3 2018($0.06)($0.07)($0.01)($0.67)$0.75 million$0.98 million
8/2/2018Q2 2018($0.09)($0.06)+$0.03($0.09)$0.33 million$2.55 million
8/2/2018Q2 2018($0.09)($0.06)+$0.03($0.09)$0.33 million$2.55 million
8/2/2018Q2 2018($0.09)($0.06)+$0.03($0.09)$0.33 million$2.55 million
5/10/2018Q1 2018($0.08)($0.09)($0.01)$0.32$0.83 million$0.70 million
5/10/2018Q1 2018($0.08)($0.09)($0.01)$0.32$0.83 million$0.70 million
5/10/2018Q1 2018($0.08)($0.09)($0.01)$0.32$0.83 million$0.70 million
3/15/2018Q4 2017($0.06)($0.08)($0.02)$0.42$2.38 million$1.00 million
3/15/2018Q4 2017($0.06)($0.08)($0.02)$0.42$2.38 million$1.00 million
3/15/2018Q4 2017($0.06)($0.08)($0.02)$0.42$2.38 million$1.00 million
11/9/2017Q3 2017($0.09)($0.05)+$0.04($0.22)$1.69 million
11/9/2017Q3 2017($0.09)($0.05)+$0.04($0.22)$1.69 million
11/9/2017Q3 2017($0.09)($0.05)+$0.04($0.22)$1.69 million
8/2/2017Q2 2017($0.09)($0.05)+$0.04$0.01$0.38 million
8/2/2017Q2 2017($0.09)($0.05)+$0.04$0.01$0.38 million
8/2/2017Q2 2017($0.09)($0.05)+$0.04$0.01$0.38 million
5/10/2017Q1 2017($0.09)($0.08)+$0.01($0.62)$0.39 million
5/10/2017Q1 2017($0.09)($0.08)+$0.01($0.62)$0.39 million
5/10/2017Q1 2017($0.09)($0.08)+$0.01($0.62)$0.39 million
11/3/2016Q3 2016($0.20)($0.08)+$0.12($0.46)$1.46 million$1.50 million
11/3/2016Q3 2016($0.20)($0.08)+$0.12($0.46)$1.46 million$1.50 million
11/3/2016Q3 2016($0.20)($0.08)+$0.12($0.46)$1.46 million$1.50 million
8/9/2016Q2 2016($0.17)($0.11)+$0.06($0.48)$2.15 million$1.27 million
8/9/2016Q2 2016($0.17)($0.11)+$0.06($0.48)$2.15 million$1.27 million
8/9/2016Q2 2016($0.17)($0.11)+$0.06($0.48)$2.15 million$1.27 million
5/10/2016Q1 2016($0.12)($0.19)($0.07)($0.19)$1.36 million$2.07 million
5/10/2016Q1 2016($0.12)($0.19)($0.07)($0.19)$1.36 million$2.07 million
5/10/2016Q1 2016($0.12)($0.19)($0.07)($0.19)$1.36 million$2.07 million
3/15/2016Q4 2015($0.16)($0.16)($0.16)$1.31 million
3/15/2016Q4 2015($0.16)($0.16)($0.16)$1.31 million
3/15/2016Q4 2015($0.16)($0.16)($0.16)$1.31 million
11/9/2015Q3 2015($0.18)($0.18)($0.18)$2.31 million
11/9/2015Q3 2015($0.18)($0.18)($0.18)$2.31 million
11/9/2015Q3 2015($0.18)($0.18)($0.18)$2.31 million
8/10/2015Q2 2015($0.12)($0.12)($0.12)$2.01 million
8/10/2015Q2 2015($0.12)($0.12)($0.12)$2.01 million
8/10/2015Q2 2015($0.12)($0.12)($0.12)$2.01 million
5/11/2015Q1 2015($0.13)($0.13)($0.13)$1.26 million
5/11/2015Q1 2015($0.13)($0.13)($0.13)$1.26 million
5/11/2015Q1 2015($0.13)($0.13)($0.13)$1.26 million
3/11/2015Q4 2014($0.14)($0.14)($0.14)$1.89 million
3/11/2015Q4 2014($0.14)($0.14)($0.14)$1.89 million
3/11/2015Q4 2014($0.14)($0.14)($0.14)$1.89 million
11/10/2014Q3 2014($0.12)($0.12)($0.12)$1.19 million
11/10/2014Q3 2014($0.12)($0.12)($0.12)$1.19 million
11/10/2014Q3 2014($0.12)($0.12)($0.12)$1.19 million
8/12/2014Q2 2014($0.16)($0.16)($0.16)$1.11 million
8/12/2014Q2 2014($0.16)($0.16)($0.16)$1.11 million
8/12/2014Q2 2014($0.16)($0.16)($0.16)$1.11 million
5/12/2014Q1 2014($0.14)($0.14)($0.14)$1.07 million
5/12/2014Q1 2014($0.14)($0.14)($0.14)$1.07 million
5/12/2014Q1 2014($0.14)($0.14)($0.14)$1.07 million
3/17/2014Q4 2013($0.35)($0.35)($0.35)$1.89 million
3/17/2014Q4 2013($0.35)($0.35)($0.35)$1.89 million
3/17/2014Q4 2013($0.35)($0.35)($0.35)$1.89 million
11/12/2013Q3 2013($0.16)($0.16)($0.16)$0.71 million
11/12/2013Q3 2013($0.16)($0.16)($0.16)$0.71 million
11/12/2013Q3 2013($0.16)($0.16)($0.16)$0.71 million
8/9/2013Q2 2013($0.14)($0.14)($0.14)$1.22 million
8/9/2013Q2 2013($0.14)($0.14)($0.14)$1.22 million
8/9/2013Q2 2013($0.14)($0.14)($0.14)$1.22 million
5/10/2013Q1 2013($0.15)($0.15)($0.15)$0.61 million
5/10/2013Q1 2013($0.15)($0.15)($0.15)$0.61 million
5/10/2013Q1 2013($0.15)($0.15)($0.15)$0.61 million












Lineage Cell Therapeutics Earnings - Frequently Asked Questions

When is Lineage Cell Therapeutics's earnings date?

Lineage Cell Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 8th, 2023 based off last year's report dates. Learn more on LCTX's earnings history.

Did Lineage Cell Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) missed the analysts' consensus estimate of ($0.03) by $0.01 with a reported earnings per share (EPS) of ($0.04). Learn more on analysts' earnings estimate vs. LCTX's actual earnings.

How much revenue does Lineage Cell Therapeutics generate each year?

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a recorded annual revenue of $4.34 million.

How much profit does Lineage Cell Therapeutics generate each year?

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a recorded net income of -$43.02 million. LCTX has generated -$0.29 earnings per share over the last four quarters.

What is Lineage Cell Therapeutics's EPS forecast for next year?

Lineage Cell Therapeutics's earnings are expected to decrease from ($0.15) per share to ($0.17) per share in the next year.

More Earnings Resources from MarketBeat

Earnings Tools:
Earnings By Country:
Latest Articles:
Upcoming Earnings:
This page (NYSEAMERICAN:LCTX) was last updated on 2/6/2023 by MarketBeat.com Staff